Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma

Li Ting Wang, Shyh Shin Chiou, Chee Yin Chai, Edward Hsi, Shen Nien Wang, Shau Ku Huang, Shih Hsien Hsu

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Histone deacetylase 8 (HDAC8), a unique member of class I histone deacetylases, shows remarkable correlation with advanced disease stage and multiple malignant tumors However, little is known about the contribution of HDAC8 to the tumorigenesis of hepatocellular carcinoma (HCC). The present study investigated the expression of HDAC8 regulated by the aryl hydrocarbon receptor (AHR) in HCC cell lines and tissues, and the roles of HDAC8 overexpression in cell proliferation, including potentially underlying mechanisms. We assessed the correlation between the clinic-pathological parameters and the expression of AHR and HDAC8. Further, we analyzed the AHR siRNA transfection and HDAC8 inhibitors to explore the functions of HDAC8 in HCC progression in vitro and in vivo. In a panel of 289 HCC patients, HDAC8 was shown to be highly correlated with AHR expression at both mRNA and protein levels. HCC patients with high AHR expression showed a shorter survival time than that with low AHR expression. We then found that the expression of both AHR and HDAC8 was significantly upregulated in both HCC cell lines and tumor tissues compared to human normal hepatocytes and matched non-tumor tissues. Furthermore, HDAC8 inhibition remarkably inhibited hepatoma cell proliferation and transformation activity via upregulation of RB1 in vitro and in vivo. Our data revealed an important role of the AHR-HDAC8 axis in promoting HCC tumorigenesis, thus identifying HDAC8 as a potential therapeutic target for HCC treatment.

Original languageEnglish
Pages (from-to)7489-7501
Number of pages13
JournalOncotarget
Volume8
Issue number5
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Fingerprint

Aryl Hydrocarbon Receptors
Histone Deacetylases
Hepatocellular Carcinoma
Neoplasms
Carcinogenesis
Cell Proliferation
Histone Deacetylase Inhibitors
Tumor Cell Line
Small Interfering RNA
Transfection
Hepatocytes
Up-Regulation

Keywords

  • AHR
  • HDAC8
  • Hepatocellular carcinoma (HCC)

ASJC Scopus subject areas

  • Oncology

Cite this

Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma. / Wang, Li Ting; Chiou, Shyh Shin; Chai, Chee Yin; Hsi, Edward; Wang, Shen Nien; Huang, Shau Ku; Hsu, Shih Hsien.

In: Oncotarget, Vol. 8, No. 5, 01.01.2017, p. 7489-7501.

Research output: Contribution to journalArticle

Wang, Li Ting ; Chiou, Shyh Shin ; Chai, Chee Yin ; Hsi, Edward ; Wang, Shen Nien ; Huang, Shau Ku ; Hsu, Shih Hsien. / Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 5. pp. 7489-7501.
@article{e2c47262f6c94b2c915a5b9bac1b5cb4,
title = "Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma",
abstract = "Histone deacetylase 8 (HDAC8), a unique member of class I histone deacetylases, shows remarkable correlation with advanced disease stage and multiple malignant tumors However, little is known about the contribution of HDAC8 to the tumorigenesis of hepatocellular carcinoma (HCC). The present study investigated the expression of HDAC8 regulated by the aryl hydrocarbon receptor (AHR) in HCC cell lines and tissues, and the roles of HDAC8 overexpression in cell proliferation, including potentially underlying mechanisms. We assessed the correlation between the clinic-pathological parameters and the expression of AHR and HDAC8. Further, we analyzed the AHR siRNA transfection and HDAC8 inhibitors to explore the functions of HDAC8 in HCC progression in vitro and in vivo. In a panel of 289 HCC patients, HDAC8 was shown to be highly correlated with AHR expression at both mRNA and protein levels. HCC patients with high AHR expression showed a shorter survival time than that with low AHR expression. We then found that the expression of both AHR and HDAC8 was significantly upregulated in both HCC cell lines and tumor tissues compared to human normal hepatocytes and matched non-tumor tissues. Furthermore, HDAC8 inhibition remarkably inhibited hepatoma cell proliferation and transformation activity via upregulation of RB1 in vitro and in vivo. Our data revealed an important role of the AHR-HDAC8 axis in promoting HCC tumorigenesis, thus identifying HDAC8 as a potential therapeutic target for HCC treatment.",
keywords = "AHR, HDAC8, Hepatocellular carcinoma (HCC)",
author = "Wang, {Li Ting} and Chiou, {Shyh Shin} and Chai, {Chee Yin} and Edward Hsi and Wang, {Shen Nien} and Huang, {Shau Ku} and Hsu, {Shih Hsien}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9841",
language = "English",
volume = "8",
pages = "7489--7501",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "5",

}

TY - JOUR

T1 - Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma

AU - Wang, Li Ting

AU - Chiou, Shyh Shin

AU - Chai, Chee Yin

AU - Hsi, Edward

AU - Wang, Shen Nien

AU - Huang, Shau Ku

AU - Hsu, Shih Hsien

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Histone deacetylase 8 (HDAC8), a unique member of class I histone deacetylases, shows remarkable correlation with advanced disease stage and multiple malignant tumors However, little is known about the contribution of HDAC8 to the tumorigenesis of hepatocellular carcinoma (HCC). The present study investigated the expression of HDAC8 regulated by the aryl hydrocarbon receptor (AHR) in HCC cell lines and tissues, and the roles of HDAC8 overexpression in cell proliferation, including potentially underlying mechanisms. We assessed the correlation between the clinic-pathological parameters and the expression of AHR and HDAC8. Further, we analyzed the AHR siRNA transfection and HDAC8 inhibitors to explore the functions of HDAC8 in HCC progression in vitro and in vivo. In a panel of 289 HCC patients, HDAC8 was shown to be highly correlated with AHR expression at both mRNA and protein levels. HCC patients with high AHR expression showed a shorter survival time than that with low AHR expression. We then found that the expression of both AHR and HDAC8 was significantly upregulated in both HCC cell lines and tumor tissues compared to human normal hepatocytes and matched non-tumor tissues. Furthermore, HDAC8 inhibition remarkably inhibited hepatoma cell proliferation and transformation activity via upregulation of RB1 in vitro and in vivo. Our data revealed an important role of the AHR-HDAC8 axis in promoting HCC tumorigenesis, thus identifying HDAC8 as a potential therapeutic target for HCC treatment.

AB - Histone deacetylase 8 (HDAC8), a unique member of class I histone deacetylases, shows remarkable correlation with advanced disease stage and multiple malignant tumors However, little is known about the contribution of HDAC8 to the tumorigenesis of hepatocellular carcinoma (HCC). The present study investigated the expression of HDAC8 regulated by the aryl hydrocarbon receptor (AHR) in HCC cell lines and tissues, and the roles of HDAC8 overexpression in cell proliferation, including potentially underlying mechanisms. We assessed the correlation between the clinic-pathological parameters and the expression of AHR and HDAC8. Further, we analyzed the AHR siRNA transfection and HDAC8 inhibitors to explore the functions of HDAC8 in HCC progression in vitro and in vivo. In a panel of 289 HCC patients, HDAC8 was shown to be highly correlated with AHR expression at both mRNA and protein levels. HCC patients with high AHR expression showed a shorter survival time than that with low AHR expression. We then found that the expression of both AHR and HDAC8 was significantly upregulated in both HCC cell lines and tumor tissues compared to human normal hepatocytes and matched non-tumor tissues. Furthermore, HDAC8 inhibition remarkably inhibited hepatoma cell proliferation and transformation activity via upregulation of RB1 in vitro and in vivo. Our data revealed an important role of the AHR-HDAC8 axis in promoting HCC tumorigenesis, thus identifying HDAC8 as a potential therapeutic target for HCC treatment.

KW - AHR

KW - HDAC8

KW - Hepatocellular carcinoma (HCC)

UR - http://www.scopus.com/inward/record.url?scp=85018931488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018931488&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9841

DO - 10.18632/oncotarget.9841

M3 - Article

VL - 8

SP - 7489

EP - 7501

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -